Alvotech (ALVO)

Market Cap	1.37B -64.3%
Revenue (ttm)	573.35M +45.6%
Net Income	69.50M
EPS	0.24
Shares Out	313.02M
PE Ratio	18.20
Forward PE	31.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	819,466
Open	4.650
Previous Close	4.640
Day's Range	4.340 - 4.660
52-Week Range	4.320 - 12.890
Beta	0.12
Analysts	Buy
Price Target	9.25 (+111.67%)
Earnings Date	Mar 25, 2026

About ALVO

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 1,012
• Stock Exchange: NASDAQ
• Ticker Symbol: ALVO
• Website: https://www.alvotech.com

Financial Performance

In 2024, Alvotech's revenue was $491.98 million, an increase of 426.84% compared to the previous year's $93.38 million. Losses were -$231.86 million, -57.98% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for ALVO stock is "Buy." The 12-month stock price target is $9.25, which is an increase of 111.67% from the latest price.

Price Target

$9.25

(111.67% upside)

Analyst Consensus: Buy